Adeza Biomedical Announces Dean R. Koch as Director of U.S. Sales.

SUNNYVALE, Calif.--(BW HealthWire)--Oct. 21, 1997--Adeza Biomedical has appointed Dean R. Koch as its Director of U.S. Sales with the primary responsibility being the U.S. sales of the Fetal Fibronectin (fFN) Test, Adeza's FDA-approved diagnostic test for preterm delivery.

Koch comes to Adeza from Chiron Diagnostics where he was worldwide oncology manager responsible for launching new cancer markers to laboratories, physicians and payors. Prior to Chiron, Koch worked in sales and marketing at Hybritech Diagnostics. He has experience with direct sales of immunodiagnostic products and distributor sales of point-of-care products.

Emory V. Anderson, Adeza's president stated: "Mr. Koch is an important addition to Adeza's Sales and Marketing group. We believe that his efforts will significantly impact the sales activities of the fFN Test and will help make the fFN Test widely available to physicians, hospitals and clinical laboratories so that all pregnant women and their doctors can have access to this potentially life-saving test in a timely manner."

Adeza's fFN Test is the only immunodiagnostic test approved by the FDA for assessing the risk of preterm delivery and represents a significant advance over other current evaluation techniques. Each year in the U.S. approximately 10% of all pregnancies, more than 400,000, result in preterm delivery, which is the leading cause of infant mortality and morbidity. Currently, more than $5 billion is spent in the U.S. each year on procedures related to preterm delivery.

Adeza Biomedical Corp. is a Sunnyvale, California-based biotechnology company that develops, manufactures and markets biomedical products and services specifically for women's pregnancy and reproductive health care problems including premature and late birth, infertility, endometriosis and preeclampsia.

CONTACT: Adeza Biomedical Corp., Sunnyvale

Marian E. Sacco, 408/745-0975